室心律失常的药物治疗目前的困惑与挑战.pptVIP

* * * * * * * * * * N Engl J Med 2008; 358: 2678-87 ANDROMEDA TRIAL ANDROMEDA TRIAL All-Cause Mortality: total: 37 pts Dronedarone group: 25 pts Placebo group: 12 pts HR 2.13，P=0.03 In January 2003, the data and safety monitoring board recommended that the trial be terminated for safety reasons, owing to an excess of deaths in the dronedarone group In patients with severe heart failure and left ventricular systolic dysfunction, treatment with dronedarone was associated with increased early mortality related to the worsening of heart failure N Engl J Med 2008; 358: 2678-87 室性心律失常药物治